While I'm waiting for Don to tell me how clinical data found its way into our trial results, that came neither from treated patients, nor those who received a placebo, let me ask you if you know how many US Covid deaths came from the vaccinated versus the unvaccinated patients? I would appreciate knowing that.
In this thread, you told rstar, "If the unvaccinated got vaccinated, they wouldn't end up in the hospital and thus, there would be be no risk to the health system."
In your response to kairos, you accurately report that Israel has seen, "...7.7k deaths and 1.1 million COVID cases," as if to dismiss any notion of their medical resources having been stretched to the limit.
Surely you know that Humanigen routinely now communicates how severely tested medical resources become during breakthrough infections. They have most recently reported on challenges in Minnesota and in Idaho, and prior to that, Humanigen highlighted just such the challenge in Israel to which kairos alludes. Here's some information from Israel in this regard.
"JERUSALEM, Aug 20 (Reuters) - In Israel's COVID-19 wards, doctors are learning which vaccinated patients are most vulnerable to severe illness, amid growing concerns about instances in which the shots provide less protection against the worst forms of the disease.
Around half of the country's 600 patients presently hospitalized with severe illness have received two doses of the Pfizer Inc (PFE.N) shot, a rare occurrence out of 5.4 million fully vaccinated people."
rstar is right, the vaccines do become less effective over time. kairos is correct about disease progression in vulnerable vaccinated patients. And you're correct about the favorable impact of vaccines.
But as these breakthrough infections develop, there is no real-time way of knowing whether medical personnel are fighting against a new normal infection rate, an escaped mutant virus, or how long the breakthrough infection will last, and whether or not they have the resources to see it through.
Vaccines are demonstrating success in reducing infections, but they cannot be counted on to prevent infections to the point initially reported, and even the disease progression cannot be assumed to be in control.
Lenzilumab is the way of depriving the virus of a sufficiently large host population. It will still be effective as the mu variant expands. That cannot be said of the vaccines as formulated. But we need both, unless and until lenz can be used as a prophylactic.
News 
Market Data 
Discover 
